Article Details
Retrieved on: 2022-08-26 14:48:34
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
... germline BRCA-mutated and HER2-negative high-risk breast cancer who may benefit from adjuvant treatment with AstraZeneca and Merck's Lynparza ...
Article found on: www.precisiononcologynews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here